Jefferies Financial Group Inc. Takes Position in Pfizer Inc. $PFE

Jefferies Financial Group Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 642,123 shares of the biopharmaceutical company’s stock, valued at approximately $15,462,000.

Several other large investors have also bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Pfizer in the 2nd quarter valued at about $56,549,000. MASTERINVEST Kapitalanlage GmbH acquired a new position in shares of Pfizer in the second quarter worth approximately $1,371,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in Pfizer in the second quarter valued at approximately $90,000. Blue Edge Capital LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $208,000. Finally, Strive Financial Group LLC increased its position in Pfizer by 29.9% during the 2nd quarter. Strive Financial Group LLC now owns 9,474 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 2,181 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Trading Down 1.0%

NYSE:PFE opened at $28.00 on Friday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34. The firm has a fifty day simple moving average of $25.49 and a two-hundred day simple moving average of $26.29.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.

Analyst Ratings Changes

A number of research firms have recently commented on PFE. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.